Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Conditions: ALK-positive Non-small Cell Lung Cancer; Real World Study Interventions: Drug: Lorlatinib Sponsors: Sichuan Cancer Hospital and Research Institute Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials